iTeos Therapeutics Inc. (ITOS)
NASDAQ: ITOS
· Real-Time Price · USD
7.49
0.24 (3.31%)
At close: May 01, 2025, 3:59 PM
7.50
0.13%
After-hours: May 01, 2025, 04:20 PM EDT
3.31% (1D)
| Bid | 6.1 |
| Market Cap | 286.67M |
| Revenue (ttm) | 35M |
| Net Income (ttm) | -130.81M |
| EPS (ttm) | -3.32 |
| PE Ratio (ttm) | -2.26 |
| Forward PE | -1.76 |
| Analyst | Buy |
| Ask | 7.91 |
| Volume | 924,220 |
| Avg. Volume (20D) | 387,054 |
| Open | 7.27 |
| Previous Close | 7.25 |
| Day's Range | 7.28 - 7.56 |
| 52-Week Range | 4.80 - 18.75 |
| Beta | 1.43 |
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used t...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 173
Stock Exchange NASDAQ
Ticker Symbol ITOS
Analyst Forecast
According to 3 analyst ratings, the average rating for ITOS stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 113.62% from the latest price.
Stock ForecastsEarnings Surprise
iTeos Therapeutics has released their quartely earnings
on Apr 28, 2025:
7 months ago
-27.54%
iTeos Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
8 months ago
+10.13%
iTeos Therapeutics shares are trading higher after the company announced the oral presentation of Phase 2 GALAXIES Lung-201 interim data at the European Society for Medical Oncology Congress 2024
